期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

胃肠道肿瘤k-ras突变与ERCC1 mRNA表达相关性研究 被引量：2

下载PDF
导出
摘要 目的探讨胃肠道肿瘤组织核苷酸切除修复基因ERCC1表达与k-ras基因突变的关系,为胃肠道肿瘤的个体化治疗提供理论依据。方法采用RT-PCR相对定量法检测83例胃肠道肿瘤患者癌组织ERCC1 mRNA表达水平,直接测序法检测肿瘤组织k-ras突变;分析癌组织ERCC1基因表达与k-ras突变相关基因变异的关系。结果 83份标本中19份发生k-ras突变(22.9%),ERCC1 mRNA中位表达为4.659;k-ras突变型与野生型ERCC1mRNA表达分别为3.089±2.661和4.945±2.293(P<0.01)。k-ras突变的肿瘤组织ERCC1 mRNA呈低水平表达;Pearson相关分析表明,ERCC1表达低下与k-ras基因突变发生呈正相关性(P<0.01)。结论胃肠道肿瘤k-ras突变与ERCC1 mRNA表达密切相关。
作者 孙怡 李惠 王露 王耀辉 谢玲 赖仁胜
机构地区 南京中医药大学附属医院
出处 《山东医药》 CAS 2012年第7期75-77,共3页 Shandong Medical Journal
基金 江苏高校优势学科建设工程资助项目(012062003010)
关键词 K-RAS基因 突变 ERCC1 胃肠道肿瘤
分类号 R363.25 [医药卫生—病理学]
  • 相关文献

参考文献9

  • 1Wei J,Zou Z,Qian X,et al.ERCC1 mRNA levels and survival ofadvanced gastric cancer patients treated with a modified FOLFOXregimen[J].Br J Cancer,2008,98(8):1398-1402.
  • 2刘波,韩淑梅,张国栋,朱栋元,周海燕.西妥昔单抗联合改良FOLFOX方案治疗转移性结直肠癌疗效观察[J].山东医药,2011,51(19):62-63. 被引量：5
  • 3Balin-Gauthier D,Delord JP,Pillaire MJ,et al.Cetuximab potenti-ates oxaliplatin cytotoxic effect through a defect in NER and DNAreplication initiation[J].Br J Cancer,2008,98(1):120-128.
  • 4Bacolod MD,Barany F.Molecular profiling of colon tumors:thesearch for clinically relevant biomarkers of progression,prognosis,therapeutics,and predisposition[J].Ann Surg Oncol,2011,18(13):3694-3700.
  • 5Watanabe T,Kobunai T,Yamamoto Y,et al.Gene expression sig-nature and response to the use of leucovorin,fluorouracil and oxali-platin in colorectal cancer patients[J].Clin Transl Oncol,2011,13(6):419-425.
  • 6Olaussen KA,Dunant A,Fouret P,et al.DNA repair by ERCC1in non-small-cell lung cancer and cisplatin-based adjuvant chemothera-py[J].N Engl J Med,2006,355(10):983-991.
  • 7Dahan L,Norguet E,Etienne-Grimaldi MC,et al.Pharmacogeneticprofiling and cetuximab outcome in patients with advanced colorectal cancer[J].BMC Cancer,2011,25(11):496.
  • 8Li JJ,Ding Y,Li DD,et al.The overexpression of ERCC-1is in-volved in the resistance of lung cancer cells to cetuximab combined with DDP[J].Cancer Biol Ther,2009,8(20):1914-1921.
  • 9Olaussen KA.A new step ahead for the consideration of ERCC1as a candidate biomarker to select NSCLC patients for the treatment of cetuximab in combination with cisplatin[J].Cancer Biol Ther,2009,8(20):1922-1923.

二级参考文献7

  • 1Goldberg RM, Sargent D J, Morton RF, et al. A randomized controlled trial of tluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer [J]. J Clin 0ncol,2004,22( 1 ) :23-30.
  • 2Dei Tos AP. The biology of epidermal growth factor receptor and its value as a prognostic/predictive factor [ J ]. Int J Biol Markers, 2007, 22(1 Suppl 4) :3-9.
  • 3Li S, Schmitz KR, Jeffrey PD, et al. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab[ J]. Cancer Cell, 2005,7(4) :301-311.
  • 4Tabemero J, Van Cutsem E, Diaz-Rubio E,et al. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer[ J]. J Clin Oncol,2007,25 (33) :522.5 -52-2.
  • 5Xiong JP, Zhang L, Zhong LX,et al. A phase II trial of modified FOLFOX as first-line chemotherapy in advanced colorectal cancer [J]. Antieancer Drugs,2007,18(9) :1103-1107.
  • 6Bokemeyer C, Bondarenko I, Makhson A, et al. Cetuximab plus 5- FU/FA/oxaliplutin (FOLFOX-4) versus FOLFOX-4 in the first-line treaanent of metastatic colorectal cancer (mCRC) : OPUS, a randomized phase II study[ J].J Clin Oncol, 2007,25 (suppl):172.
  • 7李红梅,冯锐,王秀美,梁军.伊立替康联合卡培他滨二线治疗晚期结直肠癌[J].中国肿瘤临床,2007,34(16):942-944. 被引量：8

共引文献4

同被引文献26

引证文献2

二级引证文献10

山东医药
2012年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部